SEC Comment Letter for Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — May 22, 2017

Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: May 22, 2017 · CIK: 0001534120 · Accession: 0000000000-17-017901

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

May 22, 2017

Author

Not clearly detected

Form

UPLOAD

Company

Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)

Letter

May 22, 2017 Uli Hacksell President and Chief Executive Officer Cerecor Inc. 400 E. Pratt Street, Suite 606 Baltimore, Maryland 21202 Cerecor Inc. Preliminary Proxy Statement on Schedule 14A Filed May 12, 2017 File No. 001-37590Re: Dear Dr. Hacksell: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare and Insurance

Show Raw Text

May 22, 2017
Uli Hacksell
President and Chief Executive Officer
Cerecor Inc.
400 E. Pratt Street, Suite 606
Baltimore, Maryland 21202
Cerecor Inc.
Preliminary Proxy Statement on Schedule 14A
Filed May 12, 2017
File No. 001-37590Re:
Dear Dr. Hacksell:
        We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence by the staff.
Division of Corporation Finance
Office of Healthcare and
Insurance

SecProbe.io